Retroviral vectors have become the primary tool for gene delivery into hematopoietic cells, including T lymphocytes. Lentiviral vectors offer an advantage over Moloney murine leukemia virus (MuLV) vectors because of their ability to translocate across an intact nuclear membrane and integrate into the genome of nonproliferating cells. We have recently demonstrated that a central strand displacement event, controlled by the central polypurine tract (cPPT) and the central termination sequence (CTS), results in the formation of a central DNA flap which acts as a cis-determinant of HIV-1 genome nuclear import. Here, we show that insertion of this DNA determinant in a classical lentiviral vector resulted in a significantly higher level of transduction in acti-
Introduction
Genetic manipulation of T lymphocytes may significantly benefit patients with various genetic or acquired hematologic disorders. Transfer of immunomodulatory and antiviral genes into T cells will enable the development of innovative therapies for cancer patients and human immunodeficiency virus type 1 (HIV-1) patients, respectively. [1] [2] [3] [4] Moreover, transfer of wild-type genes into T cells with defects in enzymatic genes such as adenosine deaminase may allow the correction of these types of disorders. [5] [6] [7] At this time, the most widely used method for gene transfer into human T cells has involved Moloney murine leukemia virus (MuLV)-based vectors. MuLVbased vectors allow stable gene transfer as the genetic material contained within the vector is integrated into target cell genomes. While this methodology holds promise, optimism has been moderated by the difficulties encountered in achieving high levels of gene transfer in clinical trials. Nevertheless, new techniques have significantly improved transduction efficiencies. Optimisations include collection of cell-free viral supernatants after culture at 32°C, co-centrifugation of supernatant with cells, multiple exposures of cells to virus as well as techniques where T cells are cocultivated with retrovirus producer 
4%). CD4
+ and CD8 + T cells were transduced at equivalent levels. Importantly, freshly isolated T cells stimulated only during the 12-h transduction period could be efficiently transduced with this new flap-containing lentiviral vector, but not with the parental lentiviral vector nor an MuLV vector. Transgene expression in the flap-containing lentiviral vector, under the control of either an internal cytomegalovirus or the elongation factor-1 alpha (EF1␣) promoter, was significant and expression remained elevated in resting T cells. Thus, this system allows stable expression of transgenes in T lymphocytes following a short ex vivo transduction protocol. Gene Therapy (2001) 8, 190-198. lines. [8] [9] [10] Additionally, it has been demonstrated that T cell transduction can be enhanced by pseudotyping virions with the gibbon ape leukemia virus (GALV) envelope rather than an amphotropic envelope. 9, 11 Finally, co-localization of retrovirus and target cells on specific adhesion domains of a recombinant fibronectin molecule has resulted in augmented transduction of T cells. [12] [13] [14] Despite these advances, a significant barrier to the use of MuLV-based vectors for T cell gene therapy remains the quiescent state of the majority of circulating T cells. The integration of oncoretroviruses such as MuLV requires mitosis, due to an inability to translocate the viral genome across an intact nuclear membrane. [15] [16] [17] Thus, primary T cells need to be stimulated before any MuLV-based gene transfer. This is clearly a hindrance to gene therapy applications for both practical and theoretical reasons: cells need to be activated during an extended period of ex vivo culture and the functional capacity of T cells may change following ex vivo stimulation. The development of lentiviral vectors can theoretically overcome this limitation since lentiviruses have evolved a mitosis-independent nuclear import strategy allowing them to integrate in nondividing cells. Indeed, vectors derived from the HIV-1 genome have recently been shown to transduce terminally differentiated nondividing cells. [18] [19] [20] [21] [22] [23] Nevertheless, lentiviral transduction of quiescent T cells has not yet been achieved. 24 It is not clear whether quiescent T cells have not been transduced because the previously employed lentiviral vectors were not optimized or alternatively, because integration of a lentiviral vector in these cells requires cell cycle progression. This latter hypothesis is based on the finding that wild-type HIV-1 infection of quiescent T cells is not successful due to a block in reverse transcription. 25 It has recently been demonstrated that the classical lentiviral vectors, which have been used to date, are not optimized for nuclear import. The viral determinants responsible for active nuclear import remain controversial, but we have shown that a plus-strand overlap, the DNA flap, acts as a cis-determinant of HIV-1 genome nuclear import. This central DNA flap is created because the reverse transcription strategy of HIV-1 involves the synthesis of two discrete half-genomic fragments with a central strand displacement event controlled in cis by the central polypurine tract (cPPT) and the central termination sequence (CTS). 26, 27 The linear DNA molecule, thus formed, bears a 99 nucleotide overlap at its center. The addition of this sequence to the classical lentiviral vector, in which the viral coding sequences between the LTRs are deleted, results in significantly enhanced nuclear import in dividing as well as non-dividing HeLa cells. 28 Moreover, we and others have found that complementation of this nuclear import defect results in enhanced transduction of human CD34 + progenitor cells. 29, 30 Here, we have assessed the capacity of this enhanced flap-containing lentiviral vector to transduce quiescent and activated primary T lymphocytes.
Results

Conditions for transduction of T cells with a TRIP lentiviral vector
We were first interested in determining optimal conditions for transduction of primary T cells using TRIP lentiviral vectors containing the central DNA flap. A schematic representation of the TRIP lentiviral vectors used in these experiments is shown in Figure 1 . In the TRIP⌬U3-EF1␣ vector, the U3 LTR sequence is deleted and EGFP transgene expression is driven from an internal EF1␣ promoter. T cells were activated for 48 h with immobilized anti-CD3 and anti-CD28 monoclonal antibodies and transductions were performed with the VSV-G-pseudotyped TRIP⌬U3-EF1␣ vector. Transductions with different quantities of virion particles, normalized by measuring the P24 content of supernatants, demonstrated a linear dose response. Specifically, following a single 12-h exposure to virion particles corresponding to 10-100 ng of P24/ml, gene transfer levels increased in a linear fashion, from approximately 10% to greater than 50% (Figure 2 ).
Co-localization of retrovirus and target cells on a recombinant fibronectin fragment (CH-296) has been shown to significantly increase gene transfer of amphotropic and GALV-pseudotyped MuLV vectors into T cells. [12] [13] [14] Transduction efficiencies with the VSV-Gpseudotyped TRIP lentiviral vector were only augmented by 10-20% in the presence of fibronectin. However, it is important to note that this increase was consistent and was observed at all tested concentrations of virion particles ( Figure 2) . Addition of the polybrene cation did not enhance gene transfer efficiencies, but rather transduction was slightly decreased. Although the dose of polybrene used in these experiments, 4 g/ml, did not appear toxic to T cells, an inhibitory effect cannot be excluded. Based on these data, all subsequent experiments were performed with a concentration of virion particles corresponding to 50 ng P24/ml in the presence of the recombinant fibronectin fragment.
Gene Therapy
Transduction of quiescent and activated T cells with lentiviral and MuLV vectors As wild-type HIV-1 cannot infect circulating peripheral T lymphocytes, most of which are in a G 0 resting state, 25 it was of significant interest to assess whether quiescent T cells could be transduced with the enhanced TRIP vector. Since variation in the efficiency of transduction can be observed between different batches of virions, all comparative experiments between the parental HR-CMV vector and the various TRIP vectors were performed with stocks of virions produced concurrently (50 ng P24/ml). It is important to underline that the reported percentages of EGFP + cells represent transduction, and not pseudotransduction or transient expression from nonintegrated vector DNA, because EGFP levels remained stable for more than 2 weeks in culture.
In agreement with results obtained with wild-type HIV-1, freshly isolated resting T cells were not transduced with the parental HR-CMV vector or with the TRIP-CMV vector ( Figure 3a ). As expected, these cells were also not transduced with a GALV-pseudotyped MuLV vector. It is nevertheless noteworthy that after a short 12-h prestimulation with ␣CD3/␣CD28 antibodies, T cells could be efficiently transduced by the TRIP-CMV vector (39.5 ± 0.7%), but not by the HR-CMV vector (11 ± 1.4%). The high levels of transduction attained with TRIP-CMV were also reached following exposure of T cells to the newly generated TRIP⌬U3-CMV and TRIP⌬U3-EF1␣ vectors (Figure 3a and data not shown). MuLV-based gene transfer remained very low (6.8 ± 0.1%), likely because mitosis is only induced after a longer stimulation with activating antibodies.
Figure 3 Kinetics of transduction of primary T cells with TRIP⌬U3-EF1␣, TRIP-CMV, HR-CMV and MuLV-5ЈLTR retroviral vectors. Following activation of freshly isolated T lymphocytes with immobilized anti-CD3/CD28 antibodies for the indicated time periods, cells were removed from the activating antibodies and exposed to cell-free retroviral supernatants for 12 h. Cells were exposed to 50 ng P24/ml of TRIP or HR viral stocks, or alternatively to GALV-pseudotyped MuLV virions. All transductions were performed on recombinant fibronectin-coated plates in the presence of recombinant IL-2 (a). Freshly isolated T cells were transduced as described above except that the 12-h exposure to cell-free retroviral supernatants was performed in the presence of anti-CD3/CD28 antibodies (concurrent stimulation/transduction) (b). Experiments were performed in duplicate and the mean numbers of EGFP
14 The augmentation in gene transduction by the TRIP vectors was also observed following a 24-h prestimulation with ␣CD3/␣CD28 antibodies. Transduction efficiencies by the TRIP-CMV, TRIP⌬U3-EF1␣ and HR-CMV vectors were 51 ± 12.7%, 71 ± 3.8% and 15 ± 1.4%, respectively. We find that this augmented level of gene transfer is specifically due to the presence of the DNA flap because transduction efficiencies obtained with a TRIPinv-CMV vector, where the central region is inserted in a reverse nonfunctional orientation, 28 were as low as those observed with the parental HR-CMV vector (data not shown).
All together, these data demonstrate that the presence of the central DNA flap in the lentiviral vector enhanced transduction of T cells which were prestimulated for only a very short time period, 12 h. Notably though, the central DNA flap was also required for optimal lentivirusmediated gene transfer in dividing T cells. This latter conclusion is based on our finding that at a time-point when MuLV-based gene transfer was very high (24-36 h) (Figure 3a) , and as such the cells were imperatively undergoing mitosis, the presence of the DNA flap continued to significantly augment lentiviral gene transfer.
For many experimental applications, it is desirable to transduce T cells immediately following their isolation. While our results obtained using the TRIP vector were very encouraging, they nonetheless precluded the immediate transduction of fresh T lymphocytes. In order to assess whether a concurrent exposure of T lymphocytes to virion particles and ␣CD3/␣CD28 antibodies would result in gene transfer, freshly isolated T lymphocytes were exposed to TRIP vector inoculums for 12 h in the presence of the stimulating anti-CD3 and anti-CD28 antibodies. Notably, these T lymphocytes were efficiently transduced with levels of 31 ± 0.5% in a representative experiment (Figure 3b ). In contrast, equivalently treated cells transduced by HR or MuLV-based vectors were transduced at insignificant levels ( Figure 3b ). Thus, we have established experimental conditions under which the TRIP vector can support gene transfer into freshly isolated lymphocytes.
Gene transfer efficiencies in CD4
+ and CD8 + T cells using TRIP and MuLV vectors The ability to transduce both CD4 + and CD8 + T cells has important implications for gene therapy strategies. It has recently been reported that the classical lentiviral vectors transduce CD8
+ T cells at significantly lower efficiencies than CD4
+ T cells (20% versus 50%). 24 Additionally, it has been suggested that GALV-pseudotyped MuLV-based virions are limited in their abilities to transduce primary CD8 + T cells. 31 We therefore compared transduction of CD4 + and CD8 + T cells with both the TRIP vector and an MuLV vector. Following activation of T cells with anti-CD3/CD28 antibodies for 24 h, lymphocytes were exposed to TRIP or MuLV virions for a 12-h period. As demonstrated in Figure 4 , both CD4
+ and CD8 + T cells were transduced to levels of greater than 50% by TRIP, as well as by MuLV vectors.
Transgene expression in mitotically active and resting T cells transduced with TRIP vectors
The major reason for generating TRIP vectors in which the transcriptional activity of the LTR was abolished (TRIP⌬U3 vectors, Figure 1) was to prevent the emergence of replication-competent recombinants. Our preliminary experiments demonstrated that the ability of the initially constructed TRIP vector and the new TRIP⌬U3 vectors to transduce primary T cells was equivalent (Figure 3 ). Interestingly though, removal of the enhancer and promoter from U3 in the 5Ј HIV LTR did result in a change in transgene expression, with a greater than sixfold increase in EGFP levels in T cells transduced with TRIP⌬U3-CMV as compared with cells transduced with the original TRIP-CMV vector (mean fluorescence intensity (MFI) of 34 versus 248) ( Figure 5 ).
Transgene expression from an internal promoter in a retroviral vector is, at least partially, dependent upon the nature of the promoter itself. Thus, we next compared transgene expression driven from the CMV immediateearly promoter with that driven from the EF1␣ promoter, because although the former has been shown to be extremely efficient in many cells types, the latter is a ubiquitous cellular promoter which is functional in quiescent cells. 32 We find that insertion of the EF1␣ pro- Gene Therapy moter, in lieu of the CMV promoter in the U3-deleted TRIP vector, was associated with an approximately equivalent level of expression in primary T cells (MFI-209). Thus, both promoters can be used to achieve high-level transgene expression.
The activation status of primary T lymphocytes may significantly affect transgene expression from an internal promoter in MuLV-based vectors. 12, 33, 34 Specifically (Figure 6a) . By 10 days after transduction, cells had returned to a resting phase, as monitored by cell cycle analysis (data not shown). Additionally, the level of EGFP expression, measured as the mean fluorescence intensity, remained stable throughout the culture period ( Figure 6b ). While these experiments were performed using TRIP⌬U3-EF1␣, equivalent results were obtained using the TRIP⌬U3-CMV vector (data not shown). Together, these data show that transgene expression from the CMV and EF1␣ internal promoters in the TRIP lentivirus-derived vector remains unchanged in activated and resting phase primary T cells.
Figure 5 EGFP transgene expression in T cells transduced with TRIP vectors. The level of EGFP expression in transduced cells, as assessed by the mean fluorescence intensity (MFI), was monitored 48 h following transduction. The MFI of cells transduced with the TRIP-CMV vector, the TRIP⌬U3-CMV vector and the TRIP⌬U3-EF1␣ vector are shown. In all three histograms, the percentage of EGFP
+ cells is between 33 and 36%.
Figure 6 Kinetics of EGFP expression in T cells transduced with the TRIP⌬U3-EF1␣ vector. T cells prestimulated with anti-CD3/CD28 antibodies were transduced with TRIP⌬U3-EF1␣ retroviral stocks (10-100 ng P24/ml). Cells were maintained in media containing recombinant IL-2 and the percentage of EGFP + cells was monitored during a 15 day period. The mean numbers of EGFP + cells are indicated and values varied by less than 10% (a). Histograms demonstrating the level of EGFP expression (MFI) at days 4, 6 and 11 after transduction with 50 ng P24/ml are shown (b). Data are representative of results obtained in three independent experiments.
Discussion
Previous gene transfer studies utilizing lentiviral vectors have been compromised because the vectors were not optimized for nuclear import. Specifically, the central DNA flap in the center of HIV-1, which acts as a cis-determinant of HIV-1 nuclear import 28 was not present in first and second generation lentiviral vectors. 19, 23, [35] [36] [37] We have recently demonstrated that introduction of this DNA flap sequence into the parental HR lentiviral vector results in a significantly higher level of nuclear import in human CD34 + hematopoietic cells. 29 In these experiments, the increased level of nuclear import translated into a striking increase in gene transduction efficiency. 29 Here, we show that inclusion of this central DNA flap resulted in a significant improvement in gene transfer into prestimulated CD4 + , as well as CD8
+ human T cells. While we detected gene transfer efficiencies of greater than 50% with the flap-containing TRIP vector, it is important to note that the majority of the experiments reported here were done under conditions where the quantity of virion particles was limiting (50 ng P24/ml). Experiments performed with higher concentrations of virions (500 ng P24/ml) resulted in a T cell transduction efficiency of greater than 80% (data not shown). The ability to achieve high levels of gene transfer in primary T cells following a short ex vivo transduction period is highly desirable for many gene therapy strategies. In this context, lentiviral vectors are superior to oncoretroviral vectors because they can reportedly integrate into the genome of nonproliferating cells and most circulating peripheral T cells are not in cycle. While lentiviral vectors have been shown to transduce noncycling macrophages and HeLa cells arrested in G 1 -S and G 2 phases of the cell cycle, 19, 22 it was not clear whether they could integrate into nonstimulated T cells. This question arose because the successful infection of quiescent CD4 lymphocytes by wild-type HIV-1 requires a transition into the G 1b stage of the cell cycle. 38 Although gene transfer into quiescent T cells has not been achieved with lentiviral vectors lacking the central DNA flap, 24 it was possible that transduction efficiencies would be augmented by the inclusion of this sequence in the TRIP vector. However, we did not observe transduction of freshly isolated T cells using the enhanced TRIP vector. An alternative explanation is that this resting population of T cells was transduced with the TRIP vector, but EGFP expression was not detected because the transgene cannot be expressed in quiescent cells. This latter possibility is nevertheless unlikely because the EF1␣ promoter present in the TRIP⌬U3-EF1␣ promoter is known to be highly functional in quiescent cells. + cells can be transduced during the G 0 phase of the cell cycle. Although we found that T cells in G 0 could not be transduced with the TRIP vector, cell division itself was not required for integration and subsequent transgene expression. Using the fluorescent dye carboxyfluorescein succinimidyl ester (CFSE) which allows distinct generations of progeny to be distinguished, 40 we determined that less than 20% of T cells had undergone division by 48 h following ␣CD3/␣CD28 stimulation (VD, unpublished observations). The high level of transduction observed in freshly isolated T cells which were immediately exposed to TRIP virions for 12 h in the presence of activating antibodies strongly indicates that gene transfer was achieved in T cells which had not yet undergone division. Importantly, cell cycle entry was not modulated in T cells stimulated with ␣-CD3/␣-CD28 antibodies only during this short 12-h period. It is also essential to underline that the EGFP expression detected in these cells reflects transduction, and not pseudotransduction or transient expression from non-integrated vector DNA, because the percentage of EGFP + cells remained essentially constant for more than 2 weeks in culture. The
Gene Therapy ability of the enhanced TRIP vector to transduce nondividing cells does not appear to be limited to T lymphocytes since we also detected efficient gene transfer in CD34
+ cells which had not undergone division during the transduction period. 29 It remains to be determined whether entry into the G 1b phase of the cell cycle is required for lentiviral transduction of all cell types, or alternatively, is a specific requirement for the transduction of T lymphocytes.
The successful transduction of both CD4 + and CD8 + T cells is important for many clinical applications. A previous study using lentiviral vectors lacking the central DNA flap reported a decreased level of transduction of CD8 + T cells versus CD4 + T cells. 24 These authors suggested that the decreased level of CD8 + T cell transduction may be due to the secretion of various inhibitory factors such as IFNs and/or an absence of factors which promote efficient lentiviral integration. In this context, it is notable that the CD8 + cells were transduced 4-6 days following T cell receptor (TCR) activation, a period during which there is a significant secretion of cytokines. 41, 42 In contrast, in our lentiviral transduction experiments which were performed at an earlier time-point, 24 h post-TCR activation, and in those reported by Costello and colleagues, 43 performed 48 h after activation, gene transfer efficiencies in CD4
+ and CD8 + T cells were equivalent. Moreover, Uckert et al 31 found that CD8 + T cells were transduced very inefficiently with a GALV-pseudotyped MuLV vector following a relatively long prestimulation (4-6 days), while we detected high MuLV-mediated transduction of CD8 + T cells following a 24-h stimulation. Thus, it is possible that transduction of CD8 + T cells with both VSV-G-pseudotyped lentiviral vectors and GALVpseudotyped MuLV-based vectors decreases when cells are prestimulated for greater than 48 h. Further studies will help to determine whether lentiviral-and MuLVmediated gene transfer into CD8 + T cells, but not CD4 + T cells, decreases following long-term TCR stimulation. If this is the case, it will be interesting to identify the factor(s) which differentially regulate lentiviral transduction in CD4 + and CD8 + T cells. Stable high level expression of the transgene of interest is a crucial parameter for gene therapy and as such, we monitored transgene expression from various lentiviral vector constructs in primary T cells. It was very auspicious that deletion of the promoter and enhancer from U3, which were eliminated in order to create a self-inactivating TRIP vector with improved biosafety, resulted in a significantly higher level of transgene expression in both T cells and CD34
+ progenitor cells (this report and FP, AD, and PC, manuscript in preparation). Specifically, transgene expression from the internal CMV promoter was approximately six-fold higher in primary T cells and three-fold higher in CD34
+ cells following deletion of the U3 sequences. The elimination of a transcriptional interference between the LTR and the internal CMV promoter likely accounts for this augmented transgene expression. Notably, these results are in agreement with those recently reported by Kung et al. 44 Specifically, they found that in T cells, transgene expression driven from an internal MuLV-based promoter in a lentiviral vector was increased following deletion of U3 sequences. Zufferey and colleagues 37 found that deletion of U3 in a second generation lentiviral vector resulted in more modest changes in CMV promoter-driven transgene expression, ranging from 0.5-fold to 2.0-fold. The apparent discrepancy between their data and those reported here is probably due to the nature of the target cell in which transgene expression was monitored (293T, HeLa, and 3T3 cells versus CD34 + and T cells). The ability of two internal promoters to drive transgene expression in the context of the TRIP lentiviral vector varied in distinct cell types. Expression of EGFP in hepatocytes and HeLa cells was two-to three-fold higher when driven from the CMV promoter as compared with the EF1␣ promoter (PC, unpublished observations). In contrast, EGFP expression in primary T cells, driven from the CMV and EF1␣ promoters, was approximately equivalent. Further studies are required to determine whether transcription factors which specifically bind and activate the EF1␣ promoter are differentially expressed in T lymphocytes, as compared with these other cell types. Nevertheless, it is important to note that transgene expression from both promoters, in the context of the TRIP⌬U3 vector, was stable in resting T cells. Thus, the TRIP⌬U3 vector offers an advantage in comparison with MuLV-based vectors as transgene expression from the latter appears to be sensitive to the activation status of the cell. 33, 34, 45 The data presented here demonstrate that primary CD4
+ and CD8 + T cells can be efficiently transduced by a VSV-G-pseudotyped TRIP lentiviral vector, even after a brief exposure to virion particles. Inclusion of the central DNA flap in the lentiviral vector was crucial for high gene transfer levels in freshly isolated, as well as prestimulated T cells. In conclusion, the use of this vector strategy for T cell-based gene therapy of genetic disorders, viral infections and cancers appears very promising.
Materials and methods
Construction of TRIP⌬U3-CMV and TRIP⌬U3-EF1␣ vectors
The KpnI-XbaI fragment of the initially described TRIP-CMV vector, 28 containing the polypurine tract and the 3ЈLTR, was subcloned into pUC18, generating the plasmid pUC-LTR. The EcoRI site was destroyed, creating pUC-LTR/RI-. A diverging PCR was performed on pUC-LTR/RI-in order to amplify the plasmid, but exclude the promoter and enhancer of the U3 sequence, using the oligonucleotides: DU3-: 5Ј-CGGAATTCGGATCCGCGGCC GCATCGATCTTGTCTTCGTTGGGAGTG-3Ј and DU3+: 5ЈCGGAATTCAGCCGTCTCGAGAGATGCTGCATATA AGCAGC-3Ј. An EcoRI site was inserted in the 5Ј and 3Ј primer sequences such that the resulting pUC-LTR⌬U3/RI-plasmid contained an EcoRI site in lieu of the 400 nucleotide U3 sequence. The TRIP⌬U3-CMV plasmid was constructed by replacing the KpnI-NheI fragment of TRIP-CMV, containing the 3Ј LTR, with the KpnI-XbaI fragment of pUC-LTR⌬U3/RI-.
The EF1␣ promoter was kindly provided by Dr S Nagata, Osaka Bioscience Institute, Japan. It was amplified using the following two primers: MluI-EF1 + : 5Ј-CTGATACGCGTCGTGAGGCTCCGGTG-3Ј and BamHI-EF1−: 5Ј-CGGGATCCTGTGTTCTGGCGGCAAAC-3Ј. The flap sequence was amplified with the two primers: EcoRI-TRIP+: 5Ј-GTCGTCGGCGCCGAATTCACAAATGGCA GTATTCATCC-3Ј and MluITRIP−: 5Ј-AGCCTCAC-GACGCGTATCAGCCAAAGTGGATCTCTGCTG-3Ј. A second round of PCR was performed on these two PCR products using the external EcoRI-TRIP+ and BamHI-EF1− primers generating a single PCR product. The TRIP-EF1␣ plasmid was generated by replacing the EcoRIBamHI fragment of TRIP-CMV with the above-described EcoRI-BamHI-digested PCR product containing the flap sequence and the EF1␣ promoter. In this construct, an MluI site has been inserted between the triplex sequence and the EF1␣ promoter. To generate the TRIP⌬U3-EF1␣ plasmid, the EcoRI-BamHI fragment of TRIP-EF1␣, containing the flap sequence and the EF1␣ promoter, was swapped with the EcoRI-BamHI fragment of TRIP⌬U3-CMV.
Virus production Virion particles containing the HR or TRIP vectors were produced by transient calcium phosphate co-transfection of 293T cells with the vector plasmid, an encapsidation plasmid lacking Vif, Vpr, Vpu and Nef accessory HIV-1 proteins (p8.91), 22, 37 and a vesicular stomatitis virus-G protein (VSV-G) envelope expression plasmid (pHCMV-G), 46 as previously described. 19 Since some variation is observed in the efficiency of transduction between different batches of virions, all comparative experiments between HR and TRIP vectors were performed with stocks of virions produced in parallel. The concentration of virion particles was normalized by measuring the P24 (HIV-1 capsid protein) content of supernatants by ELISA. Production of supernatants containing gibbon ape leukemia virus envelope (GALV)-pseudotyped MuLV vector has been previously described. 14, 47 Preparation of primary T cells and lymphocyte activation Peripheral blood samples were obtained from healthy adult donors. Peripheral blood mononuclear cells (PBMC) were separated by Ficoll-Hypaque (Sigma Aldrich, St Louis, MO, USA) density gradient centrifugation. T cell were grown in RPMI medium (GibcoBRL, Grand Island, NY, USA) with 10% FCS supplemented with recombinant IL-2 (75 U/ml) (Chiron, Emeryville, CA, USA). Before prestimulated transduction, lymphocytes (1 × 10 6 /well) were stimulated with an immobilized anti-CD3 antibody (UCHT1, 1 g/ml; the generous gift of D Cantrell, ICRF, London, UK) together with an anti-CD28 antibody (9.3, 1 g/ml; kindly provided by C June, University of Pennsylvania School of Medicine, Philadephia, PA) on non-tissue culture-treated plates for the indicated time period.
Retroviral transductions
At the indicated time-points, cells were removed from plates containing the immobilized antibodies and transduced on fibronectin-coated plates essentially as described by Moritz et al. 48 The recombinant fibronectin fragment (CH-296) which contains the connecting segment, cell-binding domain, and heparin-binding domain, 49 was kindly provided by Takara Shuzo (Otsu Shiga, Japan). Non-tissue culture-treated 24-well plates were coated with fibronectin (8 g/cm 2 ) for 2 h at room temperature. The fibronectin was then removed, plates were blocked with 1% bovine serum albumin (BSA) for 20 min at 37°C, and subsequently washed once with PBS before use. In some experiments polybrene (SigmaAldrich) (4 g/ml) was added to cells during the transduction period while in other experiments, cells were transduced on fibronectin-coated plates in the presence of immobilized anti-CD3/anti-CD28 antibodies.
Lymphocytes (1 × 10 6 ) were then incubated with lentiviral vector particles, at concentrations corresponding to 10-100 ng of viral P24/ml, for 12 h in RPMI medium containing recombinant IL-2. Alternatively, lymphocytes were exposed to 0.5 ml of cell-free MuLV retroviral supernatant under equivalent conditions. Although titers of GALV-pseudotyped MuLV particles and VSV-Gpseudotyped lentiviral particles cannot be easily compared, all comparative experiments were performed using concentrations of virions that allowed a 50% infection of cycling T cells. After a 12-h exposure to retrovirus at 37°C, cells were centrifuged and resuspended in fresh medium with IL-2. Transduction efficiencies were assessed 48 h later or as indicated. Transduced cells were identified by their FL-1 autofluorescence on a FACScan (Becton Dickinson, San Jose, CA, USA).
Monoclonal antibodies and cell surface staining PE-Cy5-conjugated anti-CD4 and anti-CD8 antibodies were obtained from Immunotech (Marseille, France). Cells were incubated with antibodies for 20 min and then washed in PBS before FACS analysis.
